

## Technology Appraisal Committee C Interests Register

### Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]

Publication Date: 06/10/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Prithwiraj Das	TAC Committee Member	Non-financial	Dr Das is employed by AstraZeneca UK as the Head of Market Access for Respiratory and Immunology therapies and Vaccines. He also noted that rosuvastatin is listed as one of the comparators but to his knowledge this is not currently promoted, and he has not been involved in work related to this appraisal.	10/05/2021	11/05/2021 16/06/2021 05/07/2021	N/A	It was agreed that this declaration would not prevent Dr Das from participating in discussions on this appraisal.
Dr Richard Nicholas	TAC Committee Member	Financial	Dr Nicholas has attended paid advisory boards for Roche and Novartis in an unrelated area.	26/04/2021	11/05/2021 16/06/2021 05/07/2021	N/A	It was agreed that this declaration would not prevent Dr Nicholas from participating in discussions on this appraisal
Dr Alan Jones	Clinical expert	Financial	Dr Jones has been the local Principal Investigator at UHB for the Oxford	12/11/2020	11/05/2021		It was agreed that this declaration would not prevent

			University sponsored ORION 4 study using inclisiran or placebo in the secondary prevention of CVD.				Dr Jones from providing expert advice to the committee.
Professor Kausik Ray	Clinical expert	Financial	Professor Ray has received honoraria for his role in ORION trial programme and acting as a consultant to Novartis and prior to that the Medicines Company. He has received honoraria from Sanofi, Amgen, Daiichi Sankyo, Esperion, Lilly, Regeneron, New Amsterdam, Silence Therapeutics, Pfizer, and Astra Zeneca for acting as a consult/ advisor on atherosclerosis and lipid lowering therapies and has also received grants from Imperial-Amgen, Sanofi, Regeneron, Daiichi-Sankyo, MSD, Pfizer	18/09/2020	11/05/2021	N/A	It was agreed that this declaration would not prevent Professor Ray from providing expert advice to the committee.
Mr Simon Williams	Patient expert	Indirect financial	HEART UK - The Cholesterol Charity has recently started work with Novartis in a different therapy area (LPa) and a CVD collaborative they are	14/10/2020	11/05/2021	N/A	It was agreed that his declaration would not prevent Mr Williams from providing expert

			about to begin work on an education programme and Novartis are also sponsoring their conference.				advice to the committee.
--	--	--	--	--	--	--	--------------------------